Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 433

1.

Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.

Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P.

Target Oncol. 2014 Sep 5. [Epub ahead of print]

PMID:
25185646
[PubMed - as supplied by publisher]
2.

[Pharmacotherapy of solid tumors : New hopes and frustrations.]

Grünwald V, Rickmann M.

Internist (Berl). 2014 Aug 21. [Epub ahead of print] German.

PMID:
25139705
[PubMed - as supplied by publisher]
3.

Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report.

Linsenmann T, Monoranu CM, Vince GH, Westermaier T, Hagemann C, Kessler AF, Ernestus RI, Löhr M.

BMC Res Notes. 2014 Aug 7;7:496. doi: 10.1186/1756-0500-7-496.

PMID:
25099491
[PubMed - in process]
Free Article
4.

Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer.

Park DJ, Thomas NJ, Yoon C, Yoon SS.

Gastric Cancer. 2014 Jul 4. [Epub ahead of print]

PMID:
24993497
[PubMed - as supplied by publisher]
5.

Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.

Peng L, Bu Z, Zhou Y, Ye X, Liu J, Zhao Q.

Tumour Biol. 2014 Jun 24. [Epub ahead of print]

PMID:
24957040
[PubMed - as supplied by publisher]
6.

Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies.

Hayman SR, Calle JC, Jatoi A, Craici IM, Wagner SJ, Weaver AL, Greene EL, Grande JP, Garovic VD.

Oncology. 2014;86(5-6):271-8. doi: 10.1159/000360180. Epub 2014 Jun 4.

PMID:
24902997
[PubMed - indexed for MEDLINE]
7.

Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.

Xu CS, Wang ZF, Dai LM, Chu SH, Gong LL, Yang MH, Li ZQ.

J Transl Med. 2014 May 27;12:148. doi: 10.1186/1479-5876-12-148.

PMID:
24884636
[PubMed - in process]
Free PMC Article
8.

Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers.

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI.

Cancer Biol Ther. 2014 Aug 1;15(8):975-81. doi: 10.4161/cbt.29187. Epub 2014 May 19.

PMID:
24842548
[PubMed - in process]
9.

A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M.

J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.

PMID:
24807156
[PubMed - in process]
10.

Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, Oude Munnink TH, Fiebrich HB, Sluiter WJ, Links TP, Walenkamp AM, de Vries EG.

J Nucl Med. 2014 May 1;55(7):1087-1092. [Epub ahead of print]

PMID:
24790218
[PubMed - as supplied by publisher]
11.

Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells.

Mathonnet M, Perraud A, Christou N, Akil H, Melin C, Battu S, Jauberteau MO, Denizot Y.

World J Gastroenterol. 2014 Apr 21;20(15):4189-96. doi: 10.3748/wjg.v20.i15.4189.

PMID:
24764657
[PubMed - in process]
Free PMC Article
12.

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R.

Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17.

PMID:
24752867
[PubMed - indexed for MEDLINE]
13.

[Pneumothorax after treatment with bevacizumab-containing chemotherapy for breast cancer - a case report].

Makino T, Kudo S, Ogata T.

Gan To Kagaku Ryoho. 2014 Feb;41(2):233-5. Japanese.

PMID:
24743204
[PubMed - indexed for MEDLINE]
14.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI.

Invest New Drugs. 2014 Aug;32(4):700-9. doi: 10.1007/s10637-014-0089-2. Epub 2014 Apr 9.

PMID:
24711126
[PubMed - in process]
Free PMC Article
15.

Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.

Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J Jr, White L, Quinn R, DeBusk LM, Flinn IW.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83. doi: 10.1016/j.clml.2014.02.010. Epub 2014 Feb 28.

PMID:
24679633
[PubMed - in process]
16.

Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.

Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D'Angelica MI, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR.

Ann Surg Oncol. 2014 Aug;21(8):2675-83. doi: 10.1245/s10434-014-3649-y. Epub 2014 Mar 25.

PMID:
24664624
[PubMed - in process]
18.

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD.

Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17.

PMID:
24633809
[PubMed - indexed for MEDLINE]
19.

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.

Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6.

PMID:
24613126
[PubMed - indexed for MEDLINE]
20.

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH.

Ann Oncol. 2014 Jun;25(6):1172-8. doi: 10.1093/annonc/mdu107. Epub 2014 Mar 7.

PMID:
24608198
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk